Brain Tumor Cell Targeting Technology: Data to Be Presented at the Society of Neuro-Oncology Quadrennial Meeting
(firmenpresse) - TORONTO, ONTARIO -- (Marketwired) -- 11/20/13 -- Arch Biopartners Inc (Arch) or (the Company) (CNSX: ACH)(OTCBB: FOIFF) announced today that data relating to proprietary technology identifying brain tumor targeting peptides developed by Dr. Stephen Robbins, Dr. Donna Senger and Dr. Jennifer Rahn and their colleagues at the University of Calgary will be presented on Nov 24, 2013 at the 4th Quadrennial Meeting of the World Federation of Neuro-Oncology being held in conjunction with the 18th Annual Meeting of the Society for Neuro-Oncology taking place in San Francisco, November 21-24.
The presentation will describe how Dr. Robbins and his colleagues used a panel of peptides to successfully image a range of diffuse infiltrating brain tumours that are notoriously difficult to image using standard MRI. Additionally, they identified peptides that possess the ability to inhibit cell invasion, or target subsets of tumour cells that had 'stem-like' properties. Thus, in addition to imaging, these peptides may be useful as therapeutics, as delivery agents for chemotherapeutics, or as diagnostic indicators.
About Arch Biopartners
Arch Biopartners is a portfolio based biotechnology company established to develop new products and technology for sale to pharmaceutical and industrial companies. The Company's lead technology is in the area of targeting brain tumor initiating cells for the purpose of developing new imaging, diagnostic and therapeutic treatments for malignant glioma. The Company's website address is: .
For more information on the Company, please consult the other public documents filed on SEDAR at .
Forward-Looking Statements
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management's estimates or opinions change.
The CNSX has not reviewed and does not accept responsibility for the adequacy of this release.
Contacts:
Arch Biopartners Inc.
Richard Muruve
CEO
(647) 428 7031
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 20.11.2013 - 14:10 Uhr
Sprache: Deutsch
News-ID 318699
Anzahl Zeichen: 7084
contact information:
Town:
TORONTO, ONTARIO
Kategorie:
Biotech
Diese Pressemitteilung wurde bisher 222 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Brain Tumor Cell Targeting Technology: Data to Be Presented at the Society of Neuro-Oncology Quadrennial Meeting"
steht unter der journalistisch-redaktionellen Verantwortung von
Arch Biopartners Inc. (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
